Abstract In December 2014, the FDA approved olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi) for ovarian cancer patients who have failed three or more lines of chemotherapy and have a germline BRCA1/2 mutation identified through a companion diagnostic test (BRACAnalysis CDx™ (CDx™)) offered exclusively by Myriad Genetic Laboratories. This study explored the impact of PARPi/CDx™ on genetic counselors' (GCs) counseling and testing practices. One hundred twenty three GCs responded to an online survey regarding preand post-FDA approval referral patterns, testing strategies/influences, and anecdotal experiences with insurance coverage of PARPi for BRCA1/2 positive patients through a non-CDx™ platform. Following PARPi approval, 40% of respondents reported an increase in overall referrals of ovarian cancer patients and 20% had an increase in post-test counseling only referrals. The majority (61.9%) of respondents reported no change in genetic testing strategy, and there was no change in factors influencing choice of testing laboratory. Nearly all (98.1%) respondents who had experience with insurance covering PARPi indicated approval with mutations identified via non-CDx™ testing. Respondents indicated an increase in referral volume following FDA approval of PARPi/CDx™, but did not report changes in testing practices. Respondents were not aware of PARPi insurance coverage denial in the absence of CDx™.
Background
In the United States, approximately 22,280 women are diagnosed with ovarian cancer each year (National Cancer Institute 2016) . Ovarian cancer is the fourth leading cause of cancer deaths for women (Quick and Natarajan 2005) , with a five-year survival rate of 46.2% (National Cancer Institute 2016) . Most ovarian cancer patients have disease that is initially responsive to platinum and taxane-based chemotherapy, however despite this, the median progression-free survival is merely 18 months ). Additionally, platinumsensitive ovarian cancers become more resistant with each disease relapse, necessitating the need for new and more effective therapies.
Up to 24% of ovarian cancer diagnoses are due to germline mutations in cancer susceptibility genes (Walsh et al. 2011) . The majority of these hereditary cases are due to germline mutations in BRCA1 and BRCA2, which cause hereditary breast and ovarian cancer syndrome (HBOC). In women with BRCA1/2 germline mutations, the lifetime risk of ovarian cancer is 24-54% and 11-27%, respectively (Antonious et al. 2003; King et al. 2003; Chen and Parmigiani 2007) .
BRCA1/2 play a key role in the homologous recombination DNA repair pathway (Gudmundsdottir and Ashworth 2006) . Studies have shown that cell lines with BRCA1/2 mutations are sensitive to treatment with poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) (Bryant et al. 2005; Farmer et al. 2005) . With the use of PARPi, BRCA1/2-deficient cells undergo synthetic lethality, killing the cell and becoming a potential target for drug therapies (Helleday 2010; Javle and Curtin 2011; Yap et al. 2011) . Several studies showed success of PARPi and the synthetic lethal relationship in BRCA1/2--deficient cells (Bryant et al. 2005; Farmer et al. 2005; Fong et al. 2009 ). Olaparib (Lynparza; AZD2281; AstraZeneca) is a selective PARPi showing success in various Phase I and II trials (Audeh et al. 2010; Fong et al. 2009; Fong et al. 2010; Gelmon et al. 2011; Kaufman et al. 2015; Tutt et al. 2010) . In December of 2014, the FDA approved the clinical use of olaparib to treat women with ovarian cancer who have failed three or more lines of chemotherapy, and who have BRCA1/2 germline mutations detected on a companion diagnostic test. BRACAnalysis Companion Diagnostic (CDx™) testing is a specific companion diagnostic test that evaluates BRCA1/2 genes using sequencing and deletion/duplication analysis, offered exclusively through Myriad Genetic Laboratories (Myriad). As there are many genetic testing companies that offer BRCA1/2 sequencing and deletion/duplication analysis, not every patient who is suspected to have a BRCA1/2 mutation is likely to be tested through Myriad and/or the CDx™ test.
There are no studies to date that assess the impact of the FDA approval of olaparib and CDx™ on genetic counseling and testing practices. We surveyed genetic counselors to assess whether these events have changed the referral process and genetic testing strategy for ovarian cancer patients. Lastly, we collected providers' anecdotal experiences with insurance coverage of PARPi treatment for BRCA1/2 positive patients identified through a non-CDx™ platform.
Methods
This study was completed through a 46-question electronic survey assessing whether FDA approval of CDx™ testing had any impact on types of genetic counseling referrals for ovarian cancer patients, volume of these referrals, whether the genetic testing processes have changed for these patients, as well as anecdotal experience from respondents on whether insurance companies are covering the cost of PARPi for patients who have not undergone CDx™ testing. The survey was sent via SurveyMonkey™ to active members of the National Society of Genetic Counselors' (NSGC) Familial Cancer Risk Special Interest Group (Cancer SIG), with approximately 1056 members as of January 2016. Eligibility criteria included being a genetic counselor currently working in the United States, in clinical practice for at least two years, as well as providing genetic counseling to at least one ovarian cancer patient per month. The Northwestern University Institutional Review Board approved the study in September, 2015.
Statistical analyses were conducted using SPSS. Descriptive statistics including frequencies and percentages were used to summarize close-ended questions, including demographic information. Pearson's Chi-squared test was used to compare the sample demographics to the NSGC membership demographics when applicable. Kruskal-Wallis was used to compare demographic information and responses assessing changes in referrals and testing strategy. McNemar's test was used to compare types of referral sources pre-and post-FDA approval of PARPi. Wilcoxon signed ranks test was used to compare the number of patients referred pre-and post-FDA approval of PARPi. For each analysis, p-values of less than .05 were considered statistically significant.
Results
Using data obtained from the NSGC, we estimated that approximately 621 individuals in the NSGC SIG were eligible to participate in the survey. A total of 147 responses were recorded. Twenty-four respondents were excluded based on failure to meet inclusion criteria (n = 22) or failure to answer eligibility criteria questions (n = 2). Therefore, a total of 123 responses were included in the analysis, with an estimated response rate of 19.8%. The majority of respondents were female (n = 89/91; 97.8%), between the ages of 25 and 34 (n = 52/90; 57.8%), had <10 years' experience working in genetic counseling (n = 66/91; 72.5%), and worked in a public hospital/medical facility (n = 56/91; 61.5%) ( Table 1 ). There were no significant differences in the study's demographic information to NSGC membership demographics.
Respondents were asked whether the number of referrals they received for ovarian cancer patients per month changed pre-vs. post-FDA approval of PARPi. Approximately 41% (45/111) of respondents indicated an increase in referrals, 6% (7/111) indicated a decrease in referrals, and the remaining 53% (59/111) indicated no change in referrals of ovarian cancer patients. Pre-FDA approval, the majority (n = 79/113; 70.3%) reported receiving, on average, 1-4 referrals, followed by 5-9 referrals (n = 22/113; 19.5%). Post-FDA approval, the number of participants receiving 1-4 referrals decreased to 59.6% (65/111), whereas the number receiving 5-9 referrals increased to 30.6% (34/111) (Fig. 1 ). This increase in referrals for ovarian cancer patients post-FDA approval of PARPi and CDx™ testing, was statistically significant (p-value = .003). Respondents were then asked to indicate changes in referral volume for patients at three specific time points during treatment for their ovarian cancers: newly diagnosed patients, those currently undergoing treatment and patients who failed at least three lines of therapy. A similar percent of respondents indicated an increase in referrals for all three time points at 35.5% (39/110), 40.0% (44/110), and 35.8% (39/109), respectively.
Respondents were next asked to report on the medical specialty referring the greatest number of ovarian cancer patients pre-and post-FDA approval. The majority of respondents reported that the largest referral source were treating oncologists both pre-(n = 97/110; 88.2%) and post-FDA approval (n = 101/110; 91.8%) (p = 0.125). Additionally, respondents were asked to describe their experience with referrals for patients who were referred to have post-test counseling only (i.e., genetic testing was performed by a different provider). Nearly 57% (61/108) of respondents provide post-test counseling for patients tested by another provider and of those, 72.1% (44/61) indicated that post-test counseling referrals remained the same, and 19.7% (12/61) indicated that these referrals increased.
Next, we inquired as to whether GCs received referrals for ovarian cancer patients who had previously been tested for BRCA1/2 to undergo CDx™ testing, and whether or not they are retesting patients with CDx™. A minority of respondents indicated receiving these referrals for previously positive patients (n = 9/99; 9.1%) and previously negative patients (n = 7/ 98; 7.1%). When these referrals were received, most respondents indicated that they had retested a patient using CDx™ testing at least once. We asked respondents to elaborate on the reasons for retesting. Due to the minimal number of respondents for these questions, generalizations cannot be made about these reasons to retest; responses varied including retesting on a case-by-case basis or following consensus by their clinical genetics team. We also assesed whether GCs were receiving referrals to discuss CDx™ for non-ovarian cancer patients as well as STAT/RUSH referrals. Only 2.1% (2/97) indicated they received non-ovarian cancer patient referrals and 20.6% (20/97) reported STAT/RUSH referrals to discuss CDx™. In addition to referral patterns, respondents were asked to provide insight on any changes to genetic testing practices in terms of test and laboratory choice since the approval of PARPi and CDx™ testing. First, respondents were asked to indicate their primary testing strategies for ovarian cancer patients for three scenarios: newly diagnosed ovarian cancer patients -pre-FDA approval, newly diagnosed ovarian cancer patients -post-FDA approval, and previously diagnosed patients who may be eligible for PARPi -post-FDA approval (Fig. 2) . The majority of respondents (n = 52/84; 61.9%) indicated no change in primary testing strategy across all three scenarios. However, of those who did report a change in testing practices, 65.6% (21/32) changed from a multigene panel pre-FDA approval to CDx™ with reflex to the myRisk™ multigene panel at Myriad. There were no significant differences in likelihood for respondents to indicate a change in primary testing strategy when comparing respondents of various demographics. Respondents were also asked to rank factors that influenced which laboratory they choose when ordering testing, both pre-and post-FDA approval of PARPi, and for patients at varying time points in treatment (same three scenarios as above). Rankings were on a scale of 1-8, with 1 being most important and 8 being least important, respectively. There was no change in overall ranking of factors for any of the three scenarios regardless of availability of CDx™ (Table 2) .
Lastly, respondents were asked to provide anecdotal experience on whether insurance companies were approving PARPi for patients who had a BRCA1/2 mutation identified on a platform other than CDx™. Approximately 56.5% (52/ 92) of respondents indicated that they had experience with insurance coverage for PARPi, and 98.1% (51/52) of those with this experience indicated that insurance companies were approving PARPi when the patient was found to have a BRCA1/2 mutation by a test other than CDx™.
Discussion
Historically, the practice of genetic testing for inherited susceptibility to cancer has had little or no direct impact on cancer treatment. A growing body of research showing potential exceptional response to chemotherapy when specific genetic defects are targeted is bringing these two worlds together. PARPi/CDx™ is the first example of an FDA-approved companion diagnostic which impacts both understanding of inherited cancer risk and cancer treatment options. The main objective of this study was to determine whether the FDA approval of PARPi/CDx™ impacts genetic counseling and testing practices for ovarian cancer patients. We aimed to assess the change in referral patterns, genetic testing strategies and factors influencing which laboratory to order testing from, as well as to learn genetic counselors' experiences with insurance companies covering PARPi for BRCA1/2 positive patients tested on a non-CDx™ platform.
Impact of PARPi/CDx™ on Referrals for Genetic Counseling Services
Approval of companion diagnostics could lead to an increase is genetic counseling referrals. A significant percentage of respondents (greater than 40%) indicated an overall increase in referrals of ovarian cancer patients following FDA approval of PARPi. This is not the first event to cause an increase in referrals for BRCA testing. One of the most well-known examples is known as the BAngelina Jolie effect.^, which led to a 2.5-fold increase in referrals to discuss BRCA1/2 testing was observed in comparison to the previous year across more than 20 genetics clinics in the United Kingdom, with no increase in inappropriate referrals (Evans et al. 2014) . A study assessing the impact of Myriad's direct-to-consumer (DTC) ad campaign for BRCA1/2 testing Fig. 2 Scenarios and potential genetic testing strategies provided to participants when assessing primary testing strategy, pre-and post-FDA approval of CDx™ testing before and after the DTC campaign, showed a 244% increase in referrals to Kaiser Permanente's hereditary cancer clinic in Denver, CO (Mouchawar et al. 2005) . To date, no one has evaluated the impact of the recent FDA approval of PARPi/ CDx™ and its effect on referrals for genetic counseling and testing. While the impact on referrals may not have been as widespread as the aforementioned past events, the present study shows that a subset of cancer genetics providers observed an increase in referrals following the approval of PARPi/CDx™. Given our observation that the increase in referrals occurred relatively equally for patients at varying time points of their treatment (e.g. initial diagnosis, those currently undergoing treatment, and those who failed treatment and were potentially PARPi eligible), this raises question as to whether or not the increase in referrals could be the result of universal increase in referral volume versus referring providers looking to determine PARPi/CDx™ eligibility (immediate and/or long-term). Also, given that this analysis relied on retrospective recall of patient referrals, there is risk that recall bias may be impacting the results.
This increase in referrals may not be limited to only ovarian cancer patients. Although PARPi are only approved for ovarian cancer patients at this time, a minority of respondents (2.1%) indicated that they had received referrals to discuss CDx™ testing for non-ovarian cancer patients. This implies that the majority of providers seem to appreciate the utility of olaparib is for ovarian cancer patients only. However, there are clinical trials underway evaluating PARPi for various tumors types including breast, prostate, pancreatic, and others (U.S. Institutes of Health 2016). The small number of patients referred to discuss other tumor types may increase in the near future as olaparib was recently granted Breakthrough Therapy designation (BTD) by the FDA to treat a subset of BRCA1/2 or ATM gene mutated metastatic castration-resistant prostate cancer (BLynparza (olaparib) granted Breakthrough Therapy designation,^2016). In addition, it has been suggested that PARPi could be successful for other cancers deficient in homologous recombination repair. Myriad recently released another companion diagnostic product, myChoice HRD™ (homologous recombination deficiency), aimed to identify tumors that are HR-deficient (Myriad 2015). Therefore, it is likely in the near future that companion diagnostic testing for other cancer types will become a more common indication for referral for genetic testing.
With CDx™ testing being used to guide treatment decisions, there may be circumstances when oncologists may need to order testing quickly for patients who are potentially eligible for PARPi to confirm treatment qualification, without referring their patient for pre-test counseling. Over half (56.5%) of genetic counselor respondents indicated they saw patients for post-test counseling only, with patients having testing ordered by another healthcare provider. Of those who reported seeing patients for post-test counseling, the majority indicated that there was no change in the number of referrals for this indication following approval of PARPi/CDx™, though it is worth noting that 20% of genetic counselors indicated an increase in referrals for post-test counseling. According to the American BRCA Outcomes and Utilization of Testing (ABOUT) study, 63.2% of individuals tested did not see a board-certified genetics clinician for genetic counseling prior to testing (Armstrong et al. 2015) . In the present study, the fact that 20% of respondents indicated an increase in post-test counseling referrals may be due to physicians ordering testing for patients to determine PARPi eligibility before referring to a genetics provider for counseling to discuss implications of results and/or need for further testing. Researchers should continue to assess whether genetic counselors are seeing an increase in referrals for post-test counseling, how this may change their practices, as well as patient knowledge, understanding, and anxiety levels about genetic testing and its implications. These data could be valuable in developing alternative service delivery models to address the inevitable increase in patients needing genetic testing and counseling both pre-and post-test. While we observed a number of genetic counselors receiving referrals for post-test counseling in the absence of pre-test counseling, we also wanted to gauge whether or not genetic counselors were being referred potentially eligible PARPi patients on a RUSH/STAT basis to discuss CDx™ testing. We found that a minority (2.1%) of respondents were receiving referrals for ovarian cancer patients on a RUSH/STAT basis. While it may have been expected that more patients would have been referred for RUSH testing to determine PARPi eligibility, it is also possible that gynecologic oncologists are ordering testing themselves for these patients. The frequency of receiving a RUSH referral for this indication may be dependent on when the treating physician is assessing their patient's BRCA status; if they test them at time of diagnosis, urgent testing would not be necessary. The number of RUSH referrals received may also be the result of how quickly the genetics provider can accommodate the referral.
Impact of PARPi/CDx™ on Genetic Counselors' Testing Practices
Another question posed is how genetic counselors handle patients who have undergone BRCA1/2 genetic testing before CDx™, and whether retesting with CDx™ is a consideration for these patients. While only a small percentage (16.2%) of respondents indicated receiving referrals for previously tested ovarian cancer patients (both BRCA positive and negative) for retesting with CDx™, the majority of those respondents indicated they retested at least once. The low percentage of respondents receiving referrals for this reason was initially surprising since CDx™ is marketed as necessary for PARPi coverage. However, on a technical level, CDx™ is the same as Myriad's BRCA1/2 sequencing and deletion/duplication testing, with the only difference being that CDx™ is performed in a separate, FDA-approved laboratory setting. The comments provided by respondents indicated that they did not believe CDx™ testing to be necessary for PARPi eligibility, and believed that insurance companies were likely to cover PARPi treatment as long as the patient was BRCA1/2 positive, regardless of the testing platform. It is possible that referring physicians share the same belief. However, due to the minimal number of respondents for these questions, neither conclusions nor generalizations can be made to other genetic counselors regarding what influences their decision whether or not to retest with CDx™.
Even though many respondents did not retest with CDx™, a small number of respondents indicated ordering the companion diagnostic test to confirm an already established mutation. So, while the companion diagnostic germline test is effectively the same test that has been available for many years, a small subset of providers still felt there was a reason to retest. Thus, should more companion diagnostic germline tests become available that are equivalent to testing already available, the healthcare community will need to continue to assess the financial impact of retesting patients for the sole purpose of therapy qualification, as well as to evaluate the evolving role of FDA oversight of genetic testing practices in general.
When assessing whether the availability of CDx™ testing would change genetic counselors' considerations when choosing a genetic testing laboratory to test ovarian cancer patients, we found that the most important factors pre-and post-FDA approval were the laboratory's testing options (panels, single gene, etc.) and insurance coverage. No factors changed in overall ranking pre-to post-FDA approval, and the availability of CDx™ testing was ranked as 6th most important factor out of eight choices. This alludes to the fact that genetic counselors do not feel that the availability of CDx™ is as important as other factors when choosing which laboratory to order testing from. These data regarding factors influencing genetic counselors' decisions on which laboratory to order testing from are novel, and further studies are necessary to learn more about the impact of germline companion diagnostic testing on influences for laboratory choice.
In order to determine whether companion diagnostic testing approval has had any impact on genetic testing decisions, we assessed genetic counselors' primary testing strategies preto post-FDA approval. Most (61.9%) indicated that their primary testing strategy did not change pre-to post-FDA approval. When there was a change, the most frequent change was from a multigene panel to CDx™ with reflex to the myRisk™ multigene panel. While the majority of genetic counselors maintained the same primary testing strategy regardless of PARPi approval, there is a subset of providers who have changed testing strategy to include CDx™ testing for patients who may be PARPi eligible. The fact that most did not change testing strategies may be the result of genetic counselors not thinking that CDx™ testing is truly required for PARPi treatment approval. One potential explanation for this may be that the germline companion diagnostic test available is technically the same test that has been available for many years. Moreover, other commercial genetic testing laboratories offer more genes related to ovarian and breast cancer susceptibility, which may lead to genetic counselors maintaining existing testing strategies. As more germline companion diagnostic testing becomes available, it will be interesting to assess whether this pattern continues, and what factors influence these decisions. Overall, however, it is important to note that testing strategies are in a state of flux, and the changes found in this study may not necessarily be attributed to PARPi/ CDx™ approval. For example, a survey of genetic counselors in 2013 assessed changes in testing practices following the Supreme Court decision on Myriad's patent for BRCA1/2 and for the introduction of cancer panels (Hooker et al. 2014) . They found that 93% of genetic counselors had changed the type of testing ordered for HBOC patients over the previous year, with 84% indicating a change in testing approach for at least one of four hypothetical patient scenarios. Thus, changes in testing strategies observed in our study are likely the result of numerous confounding factors and not solely the result of PARPi/CDx.
Lastly, an important question in the cancer genetics and gynecologic oncology communities is whether or not insurance companies are covering PARPi for patients who have a germline BRCA1/2 mutation identified on a platform other than CDx™. This is an important question, as it may ultimately drive testing practices (e.g., the need to retest individuals found to be positive via another platform), as well as companion testing development. We found that of those who had experience with this, the majority (98%) indicated that insurance companies cover the cost of PARPi in the absence of CDx™. These data are in line with respondents' comments about insurance coverage being an important factor influencing their decision on whether to retest patients. Although each insurance plan is different and it may vary from treatment to treatment, some insurance companies have set precedent with requiring a companion diagnostic before approving coverage of the corresponding treatment (e.g., United Healthcare for approval of Cerdelga) (United Healthcare 2016). While it appears that most insurance companies do not have such policies for olaparib based on our respondents reported experiences, this drug is newly approved for treatment and there is still a need to follow trends over time. This will become particularly important if PARPi becomes more readily approved for a wider variety of indications.
As the use of PARP inhibitors grows and companion diagnostic testing becomes more common in the cancer genetics community, future areas of study should continue to focus on how genetic counselors are incorporating this testing into clinical practice as practices are likely to change over time, particularly as the data on PARPi evolve. Additionally, there is no data directly from insurance companies describing their coverage of PARPi in the presence/absence of CDx™. As we were only able to obtain minimal anecdotal experiences of providers, this would be an interesting area of future research.
Summary
This is the first study in the literature to the authors' knowledge assessing current experiences and practices of genetic counselors surrounding germline companion genetic testing and PARPi treatment for ovarian cancer patients. Given this, one of the first strengths of the study is its timeliness to assess the immediate impact of this change, as experiences are recent and potentially more accurate than if the respondents were surveyed at a later point in time. Another strength of this study is that actual clinical experiences were assessed rather than providing hypothetical situations to respondents.
The study had a number of limitations as well; one of the most important to address is the small sample size in a number of questions due to lack of respondent experience with referrals for previously tested patients. Thus, the results cannot be interpreted as generalizable to the entire cancer genetic counselor population. In addition to the small sample size, this study was retrospective and the survey was sent out ten months after approval of CDx™. Thus, responders had to estimate the referral volume both before approval, as well as after, which would not be as accurate as a prospective study that assessed referral volume. Further, as mentioned above, it cannot be assumed that the increase in volume of referrals reported in this study was truly due to CDx™ as it could have been caused by several factors. Additionally, due to the survey being sent out to cancer genetic counselors and not being available to other providers, the results may not be generalizable to other types of clinicians (e.g., geneticists, oncologists, surgeons) who may be ordering testing for these patients nor genetic counselors who are not members of the NSGC. However, the information gathered from these questions is still important in order to shape our further understanding of how counselors approach these patients, and what factors/thoughts impact their reasons for retesting. As such, further investigation of other categories of providers' genetic testing practices surrounding CDx™ is warranted.
In summary, a substantial number of laboratories offer cancer genetic testing nationwide, but only a single laboratory offers the FDA-approved companion diagnostic for PARPi treatment. Even though companion diagnostics for drug therapy is not a new concept, this is the first FDA-approved companion diagnostic requiring germline testing as an eligibility criteria for cancer treatment. Thus, cancer genetic counselors are charting new territory on whether a companion diagnostic is truly required for the specified treatment, as well as how to handle testing and counseling practices for these patients. While our data show that choice of laboratory and type of test have not been significantly impacted among genetic counselors following FDA approval of PARPi/CDx™, the convergence of hereditary cancer testing and oncology treatment decisions through companion diagnostic testing has changed genetic counseling practices in many ways. This study supports a need to increase access to genetic counseling services to meet increasing referral volumes, including access to posttest counseling services for those tested by other healthcare providers. With the increase in precision medicine and advanced diagnostic testing becoming more readily incorporated in medical care, the need to continue assessing how genetic counselors are doing testing will be vital.
